Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy

Recruiting N/A Interventional Study
Pancreas Cancer Pancreaticoduodenal Lymphadenopathy Pancreas Adenocarcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
180 (estimated)
Sponsor
Humanitas Hospital, Italy · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Pancreaticoduodenectomy (PD) associated with lymphadenectomy is the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). In 2014, the International Study Group on Pancreatic Surgery (ISGPS) defined the "standard lymphadenectomy", that is mandatory during PD for PDAC. Lymphadenectomy should include the removal of the hepatoduodenal ligament nodes (stations 5, 6, 12…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * pre-operative radiological or histological diagnosis of pancreatic head PDAC, including PDAC arising from IPMN (invasive-IPMN) (in case of not confirmation of PDAC at final pathological examination, the case will be considered as a "drop out" and excluded from the study); * up…
Contacts

Gennaro Nappo, MD

00393471926757

gennaro.nappo@humanitas.it

CONTACT